SCHEMBL9775876

SCHEMBL9775876

O=C(CCCl)Nc1ccc(F)c(Cl)c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.69
KDM4E B2RXH2 1/20 0.64
FABP4 P15090 1/20 0.61
MEN1 O00255 5/20 0.60
KMT2A Q03164 5/20 0.60
MAPT P10636 4/20 0.60
SLC2A1 P11166 1/20 0.59
HPGD P15428 1/20 0.58
LMNA P02545 3/20 0.57
HTT P42858 2/20 0.56
ALDH1A1 P00352 1/20 0.56
NPSR1 Q6W5P4 1/20 0.56
HDAC3 O15379 1/20 0.55
EGFR P00533 1/20 0.55
HDAC4 P56524 1/20 0.55
HDAC1 Q13547 1/20 0.55
HDAC7 Q8WUI4 1/20 0.55
HDAC2 Q92769 1/20 0.55
HDAC10 Q969S8 1/20 0.55
HDAC11 Q96DB2 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23540894 0.91 TSHR (0.66) TSHRKDM4EFABP4MEN1KMT2A
SCHEMBL10032004 0.89 TSHR (0.71) TSHRKDM4EFABP4MEN1KMT2A
SCHEMBL19260238 0.87 TSHR (0.53) TSHRKDM4EFABP4MEN1KMT2A
SCHEMBL31023418 0.87 TSHR (0.73) TSHRKDM4EFABP4MEN1KMT2A
SCHEMBL4002460 0.87 TSHR (0.73) TSHRKDM4EFABP4MEN1KMT2A
SCHEMBL4052944 0.87 MAPK1 (0.58) TSHRKDM4EMEN1KMT2AMAPT
SCHEMBL20219039 0.85 TSHR (0.76) TSHRKDM4EFABP4MEN1KMT2A
SCHEMBL1878130 0.85 CYP3A4 (0.67) KDM4EMEN1KMT2AMAPTHPGD
SCHEMBL4101149 0.83 KMT2A (0.56) TSHRKDM4EMEN1KMT2AMAPT
SCHEMBL7933287 0.82 TSHR (0.71) TSHRKDM4EFABP4MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4630403-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD Pharma A/S (DK) 2025-10-15 EP disclosed
EP-3416633-B1 TETRAHYDROQUINOLINE SUBSTITUTED HYDROXAMIC ACIDS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS UNIV ILLINOIS (US) 2025-07-23 EP disclosed
WO-2024121129-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD PHARMA A/S (DK) 2024-06-13 WO disclosed
US-10456394-B2 Tetrahydroquinoline substituted hydroxamic acids as selective histone deacetylase 6 inhibitors THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2019-10-29 US disclosed
US-10456394-B2 Tetrahydroquinoline substituted hydroxamic acids as selective histone deacetylase 6 inhibitors THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2019-10-29 US disclosed
US-20190255046-A1 TETRAHYDROQUINOLINE SUBSTITUTED HYDROXAMIC ACIDS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOS (US) 2019-08-22 US disclosed
US-20190255046-A1 TETRAHYDROQUINOLINE SUBSTITUTED HYDROXAMIC ACIDS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOS (US) 2019-08-22 US disclosed
EP-3416633-A1 TETRAHYDROQUINOLINE SUBSTITUTED HYDROXAMIC ACIDS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS The Board of Trustees of the University of Illinois (US) 2018-12-26 EP disclosed
WO-2017142883-A1 TETRAHYDROQUINOLINE SUBSTITUTED HYDROXAMIC ACIDS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2017-08-24 WO disclosed
WO-2017142883-A1 TETRAHYDROQUINOLINE SUBSTITUTED HYDROXAMIC ACIDS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2017-08-24 WO disclosed
US-5053509-A Microbiocides; AIDS LABORATOIRE ROGER BELLON (FR) 1991-10-01 US disclosed
US-5004745-A Benzo[1,8]naphthyridine derivatives, their preparation and the compositions which contain them LABORATOIRE ROGER BELLON (FR) 1991-04-02 US disclosed
US-4990515-A Chemical intermediates RHONE-POULENC SANTE (FR) 1991-02-05 US disclosed
US-4970213-A Benzo(1,8)naphthyridine derivatives as intermediates RHONE-POULENC SANTE (FR) 1990-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190255046-A1 TETRAHYDROQUINOLINE SUBSTITUTED HYDROXAMIC ACIDS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS HDAC1, HDAC5, HDAC7 TSHR 3382/4885KDM4E 308/4885FABP4 3910/4885
US-10456394-B2 Tetrahydroquinoline substituted hydroxamic acids as selective histone deacetylase 6 inhibitors HDAC1, HDAC5, HDAC7 TSHR 3382/4885KDM4E 308/4885FABP4 3910/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.